DOCSLIB.ORG

Bridging Progestogens in Pregnancy and Pregnancy Prevention

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bridging Progestogens in Pregnancy and Pregnancy Prevention E Micks et al. Bridging progestogens 1–12 4:R81 Review Open Access Bridging progestogens in pregnancy and pregnancy prevention Elizabeth Micks1, Greta B Raglan2 and Jay Schulkin1,2 Correspondence 1Department of Obstetrics and Gynecology, University of Washington, Box 356460, 1959 NE Pacific Street, Seattle, should be addressed Washington, USA to E Micks 2Department of Research, American College of Obstetricians and Gynecologists, 409 12th Street SW, Washington, Email District of Columbia, USA [email protected] Abstract Steroid hormones have been in use for more than a half a century as contraceptive agents, and Key Words only now are researchers elucidating the biochemical mechanisms of action and non-target " progestogens effects. Progesterone and synthetic progestins, critical for women’s health in the US and " pregnancy internationally, appear to have important effects on immune functioning and other diverse " contraception systems. Apart from the contraceptive world is a separate field that is devoted to understanding " preterm birth progesterone in other contexts. Based on research following a development timeline parallel " collaborative research to hormonal contraception, progesterone and 17-hydroxyprogesterone caproate are now administered to prevent preterm birth in high-risk pregnant women. Preterm birth researchers are similarly working to determine the precise biochemical actions and immunological effects Endocrine Connections of progesterone. Progesterone research in both areas could benefit from increased collaboration and bringing these two bodies of literature together. Progesterone, through actions on various hormone receptors, has lifelong importance in different organ systems and researchers have much to learn about this molecule from the combination of existing literatures, and from future studies that build on this combined knowledge base. Endocrine Connections (2015) 4, R81–R92 Introduction Progesterone, progestins, and progestogens gynecologic conditions. As the number of available compounds has grown, so too has our understanding of Progesterone is a C-21 steroid hormone first identified and how they differ in terms of metabolism, pharmacokinetics, characterized by Willard Myron Allen in 1933. C-21 potency, binding affinity for the PR and other steroid steroid hormones contain 21 carbons and are also referred receptors, and effects on diverse cell types. The term to as pregnanes. This class of signaling molecules also ‘progestogen’ encompasses both natural and synthetic includes corticosteroids. Dr Allen named the compound compounds that bind the PR. progesterone, shortened from ‘progestational steroid ketone’. Many different synthetic agents that bind The need for contraceptive technology the progesterone receptor (PR), termed ‘progestins’, are now used for contraception, preterm birth prevention, Half of pregnancies in the USA are unintended (1, 2, 3). hormone therapy, and as treatment for a wide range of About half of women in the USA will have an unintended http://www.endocrineconnections.org Ñ 2015 The authors This work is licensed under a Creative Commons DOI: 10.1530/EC-15-0093 Published by Bioscientifica Ltd. Attribution-NonCommercial-NoDerivs 4.0 International License. Downloaded from Bioscientifica.com at 09/30/2021 06:36:10AM via free access Review E Micks et al. Bridging progestogens 2–12 4:R82 pregnancy by age 45, and one in three will have an Progesterone: diverse roles in different abortion (4). Worldwide, the situation is more dire as systems women with unintended pregnancy often do not have It is estimated that steroid receptors first appeared in living access to safe abortion or obstetric care. Over 280 000 organisms approximately half a billion years ago. The maternal deaths occurred in 2010 and 7.9% were due to mineralocorticoid, glucocorticoid, progesterone, and unsafe abortion (5). Improvements in contraceptive access androgen receptors are very closely related members of the as well as advancements in contraceptive technology are nuclear-receptor super-family, thought to arise in multi- needed to address these issues (6). Reducing unmet need cellular animals (9, 10). Structurally similar receptors exist for family planning represents one of the most effective in all vertebrates, and are present in some invertebrates such strategies for improving maternal health (7), and proges- as mollusks, proving their ancient origins (11, 12). togens remain one of the most promising avenues for Progesterone has diverse effects on myriad systems. It contraceptive research and development. However, there plays a role in pair bonding in birds (13), body fluid balance is evidence indicating that current methods of hormonal in humans (14), sexual differentiation in fish (15), and contraception, particularly injectable progestins, may sexual receptivity in mice (16). In human males and increase women’s risk of HIV acquisition and transmission females, progesterone has been found to have various to male sex partners (8). Lack of other contraceptive reproductive and non-reproductive functions, including options, especially for women at highest risk, is a critical immunomodulation, neuroprotection, and inhibition of barrier to progress towards optimizing women’s reproduc- cholesterol synthesis (17, 18, 19). Progesterone is one of tive health. several hormones, including Vitamin D, aldosterone, and cortisol, which all compete for similar receptor sites in both Progesterone for preterm birth prevention brain and peripheral tissue. Receptor binding and sub- sequent effects depend on the metabolic condition (20). a In 2006, progesterone and 17 -hydroxyprogesterone The role of progesterone in reproductive functioning caproate (17-OHPC) re-emerged as effective therapies for is complex in both pregnant and nonpregnant women. pregnant women at high risk for preterm delivery (delivery In a normal menstrual cycle, progesterone is critical for ! at 37 weeks gestation). In turn, scientists studying the preparing the endometrium for implantation of the mechanisms of normal and preterm birth and the role of Endocrine Connections embryo and, if implantation occurs, it is needed to reproductive hormones made important discoveries maintain the pregnancy (21, 22). If pregnancy does not regarding progestins, the PR, and related steroid receptors. occur, bleeding occurs in response to progesterone with- Research in preterm and normal labor has highlighted the drawal. Progesterone also is responsible for ovulation impact of progesterone on immune functioning. suppression during the luteal phase. In pregnant women, progesterone promotes uterine quiescence but, through Bringing two worlds together different receptors, also makes a contribution to the cascade of events leading to labor (23). Biochemists continue to elucidate the mechanisms of action of different progestins in order to identify the safest and most effective compounds for widespread use in Diverse signaling pathways contraceptives and preterm birth prevention, but research Progesterone was traditionally believed to act only in these areas tends to occur in a vacuum. Researchers in through the progesterone and other steroid receptors via both areas would benefit from following the other gene transcription and translation of genes into proteins. separately evolving field. This article aims to bring The PR is one of the best-described transcription factors. together these two related literatures, discuss the state of However, it also acts through many non-genomic mech- the science of the physiology of progestins and progester- anisms that do not require steroid receptors and protein one for these indications, and determine what conclusions transcription. Such actions are considerably faster and may be drawn about the differential effects of progestins may play crucial roles in several organ systems, especially on various organ systems, particularly the immune the brain. Non-genomic actions of progesterone include system, and how these findings might impact the activation of intracellular signaling pathways through development of contraceptive and preterm birth preven- modulation of cell surface receptors, ion channels, and tion methods. secondary messenger cascades (24).Throughthese http://www.endocrineconnections.org Ñ 2015 The authors This work is licensed under a Creative Commons DOI: 10.1530/EC-15-0093 Published by Bioscientifica Ltd. Attribution-NonCommercial-NoDerivs 4.0 International License. Downloaded from Bioscientifica.com at 09/30/2021 06:36:10AM via free access Review E Micks et al. Bridging progestogens 3–12 4:R83 mechanisms, as well as the traditional PR pathway, ways (19, 29); it both inhibits CRH production in the progesterone helps regulate cell viability in the brain. placenta and attenuates the effects of CRH. Progesterone Other examples of rapid non-genomic effects include also competes with cortisol for the same receptor sites. acceleration of oocyte maturation and stimulation of the The effect of progesterone on CRH activity depends on acrosomal reaction in spermatozoa (25). Some of these gestational age and the ratio of different PRs. effects are mediated through a different kind of PR, The role of progesterone in pregnancy maintenance sometimes referred to as ‘membrane PRs’, which may act and in labor initiation is complex and varies throughout via inhibitory G-proteins (26). pregnancy depending on the state of myometrial receptors and other factors. Nonetheless, clear evidence for the importance of progesterone in pregnancy maintenance Progestins
Load more

Recommended publications
  • Risk of Breast Cancer After Stopping Menopausal Hormone Therapy In
    Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort Agnès Fournier, Sylvie Mesrine, Laure Dossus, Marie-Christine Boutron-Ruault, Françoise Clavel-Chapelon, Nathalie Chabbert-Buffet To cite this version: Agnès Fournier, Sylvie Mesrine, Laure Dossus, Marie-Christine Boutron-Ruault, Françoise Clavel- Chapelon, et al.. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment, Springer Verlag, 2014, 145 (2), pp.535-43. 10.1007/s10549- 014-2934-6. inserm-01319982 HAL Id: inserm-01319982 https://www.hal.inserm.fr/inserm-01319982 Submitted on 23 May 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. TITLE PAGE Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort Authors : Agnès Fournier1,2,3, Sylvie Mesrine1,2,3, Laure Dossus1,2,3, Marie-Christine Boutron- Ruault1,2,3, Françoise Clavel-Chapelon1,2,3, Nathalie Chabbert-Buffet4 Affiliations: 1. Inserm, Center for research in Epidemiology and Population Health, U1018, Nutrition, Hormones and Women’s Health team, F-94807, Villejuif, France 2. Univ Paris-Sud, UMRS 1018, F-94807, Villejuif, France 3. Institut Gustave Roussy, F-94805, Villejuif, France 4.
    [Show full text]
  • Role of Synthetic and Natural Inhibitors
    Biochimica et Biophysica Acta 1845 (2014) 136–154 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbacan Review Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors Kodappully Sivaraman Siveen a,1, Sakshi Sikka a,b,1,RohitSuranaa,b, Xiaoyun Dai a, Jingwen Zhang a, Alan Prem Kumar a,b,c,d, Benny K.H. Tan a, Gautam Sethi a,b,⁎, Anupam Bishayee e,⁎⁎ a Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore b Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, Singapore c School of Biomedical Sciences, Faculty of Health Sciences, Curtin University, Western Australia, Australia d Department of Biological Sciences, University of North Texas, Denton, TX, USA e Department of Pharmaceutical Sciences, School of Pharmacy, American University of Health Sciences, Signal Hill, CA, USA article info abstract Article history: Signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic transcription factors Received 15 August 2013 that mediate intracellular signaling that is usually generated at cell surface receptors and thereby transmit it to Received in revised form 24 December 2013 the nucleus. Numerous studies have demonstrated constitutive activation of STAT3 in a wide variety of human Accepted 27 December 2013 tumors, including hematological malignancies (leukemias, lymphomas, and multiple myeloma) as well as Available online 2 January 2014 diverse solid tumors (such as head and neck, breast, lung, gastric, hepatocellular, colorectal and prostate cancers). There is strong evidence to suggest that aberrant STAT3 signaling promotes initiation and progression of human Keywords: STAT3 cancers by either inhibiting apoptosis or inducing cell proliferation, angiogenesis, invasion, and metastasis.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Potential of Guggulsterone, a Farnesoid X Receptor Antagonist, In
    Exploration of Targeted Anti-tumor Therapy Open Access Review Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer Sosmitha Girisa , Dey Parama , Choudhary Harsha , Kishore Banik , Ajaikumar B. Kunnumakkara* Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India *Correspondence: Ajaikumar B. Kunnumakkara, Cancer Biology Laboratory and DBT-AIST International Center for Translational and Environmental Research (DAICENTER), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India. [email protected]; [email protected] Academic Editor: Gautam Sethi, National University of Singapore, Singapore Received: August 8, 2020 Accepted: September 14, 2020 Published: October 30, 2020 Cite this article: Girisa S, Parama D, Harsha C, Banik K, Kunnumakkara AB. Potential of guggulsterone, a farnesoid X receptor antagonist, in the prevention and treatment of cancer. Explor Target Antitumor Ther. 2020;1:313-42. https://doi.org/10.37349/ etat.2020.00019 Abstract Cancer is one of the most dreadful diseases in the world with a mortality of 9.6 million annually. Despite the advances in diagnosis and treatment during the last couple of decades, it still remains a serious concern due to the limitations associated with currently available cancer management strategies. Therefore, alternative strategies are highly required to overcome these glitches. The importance of medicinal plants as primary healthcare has been well-known from time immemorial against various human diseases, including cancer. Commiphora wightii that belongs to Burseraceae family is one such plant which has been used to cure various ailments in traditional systems of medicine.
    [Show full text]
  • WO 2016/180764 Al 17 November 2016 (17.11.2016) P O P CT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/180764 Al 17 November 2016 (17.11.2016) P O P CT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/565 (2006.01) A61K 31/567 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP20 16/060298 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, May 2016 (09.05.2016) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 15 167521 .2 13 May 2015 (13.05.2015) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: BAYER OY [FI/FI]; Pansiontie 47, 20210 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Turku (FI). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: HOLMBERG, Svante; Hirvikoirankatu 9 A 1, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 20900 Turku (FI).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • „ Wo 2012/058463 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau „ (10) International Publication Number (43) International Publication Date . _ 3 May 2012 (03.05.2012) WO 2012/058463 A2 (51) International Patent Classification: (74) Agents: CHEN, Stephen et al; Davis Wright Tremaine A61K 31/57 (2006.01) LLP, 865 South Figueroa Street, Suite 2400, Los Angeles, California 90017 (US). (21) International Application Number: PCT/US201 1/058141 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 27 October 201 1 (27.10.201 1) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (26) Publication Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/407,388 27 October 2010 (27.10.2010) US NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, 61/434,309 19 January 201 1 (19.01 .201 1) US RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (71) Applicant (for all designated States except US): DIGNI¬ ZM, ZW. TY HEALTH [US/US]; 350 West Thomas Road, Phoenix, Arizona 85013 (US).
    [Show full text]
  • Cancer Risk an Unfortunate Truth
    Breast Cancer May 2013 Issue 30 RO F ACTs, MYTHs, VI N Cancer Risk N M an E E CHOICEs N and T unfortunate(excerpts from truth P Anand et al, 2008) GENES diet is linked to cancer deaths in as many as 70% of colorectal cancer cases. How diet contributes to cancer is not fully understood. Most carcinogens that are ingested, such as nitrates, nitrosamines, pesticides, and dioxins, come from food or food additives or from cooking. INDEX Various phytochemicals have been identified in RESEARCH PARTNERS fruits, vegetables, spices, and grains that exhibit chemopreventive potential, and numerous studies Cancer risk.....................................1 have shown that a proper diet can help protect Addictive junk food......,..................7 against cancer. Although all cancers are a result of multiple COMMUNITY PARTNERS mutations, these mutations are due to interaction with the environment. Coffee Talks..................................8 Sunchokes.......................................9 Up to 10% of total cancer cases may be Crossword puzzle.........................10 induced by radiation, both ionizing and nonionizing, typically from radioactive substances and ultraviolet Nutrient Density............................12 (UV), pulsed electromagnetic fields. Yoga Pose......................................13 Junk food and brain activity......14 Heavy consumption of red meat is a risk factor Just 4 fun.......................................15 for colorectal, prostate, bladder, breast, gastric, pancreatic, and oral cancers. Contacts Inflammation may
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Ultra-Low-Dose Oral Contraceptive Pill: a New Approach to a Conventional Requirement
    International Journal of Reproduction, Contraception, Obstetrics and Gynecology Ahuja M et al. Int J Reprod Contracept Obstet Gynecol. 2017 Feb;6(2):364-370 www.ijrcog.org pISSN 2320-1770 | eISSN 2320-1789 DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20170006 Review Article Ultra-low-dose oral contraceptive pill: a new approach to a conventional requirement Meenakshi Ahuja1, Pramod Pujari2* 1Senior Consultant Obstetrician and Gynecologist, Max Super Specialty Hospital, Saket, New Delhi, India 2Medical Advisor, Pfizer limited, Mumbai, Maharashtra, India Received: 05 December 2016 Accepted: 17 December 2016 *Correspondence: Dr. Pramod Pujari, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Combined oral contraceptives (COCs) offer a convenient, safe, effective, and reversible method of contraception. However, their use is limited by side effects. Several strategies have been suggested to make COC use more acceptable among women. Reduction in the dose of estrogen is a commonly accepted approach to reduce the side effects of COC. Use of newer generation of progestins, such as gestodene, reduces the androgenic side effects generally associated with progestogens. Furthermore, reduction in hormone-free interval, as a 24/4 regimen, can reduce the risk of escape ovulation (hence preventing contraceptive failure) and breakthrough bleeding. It also reduces hormonal fluctuations, thereby reducing the withdrawal symptoms. A COC with gestodene 60 µg and ethinylestradiol (EE) 15 µg offers the lowest hormonal dose in 24/4 treatment regimen.
    [Show full text]
  • Potential Mechanisms of Action of Kaempferol in the Prevention
    POTENTIAL MECHANISMS OF ACTION OF KAEMPFEROL IN THE PREVENTION OF BREAST CANCER A Dissertation Presented to the Faculty of the Graduate School of Cornell University in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Jinzhou Li August 2015 © 2015 Jinzhou Li POTENTIAL MECHANISMS OF ACTION OF KAEMPFEROL IN THE PREVENTION OF BREAST CANCER Jinzhou Li, Ph.D. Cornell University 2015 Epidemiological studies have shown that regular consumption of fruits and vegetables could reduce the risk of cancer. Phytochemicals in fruits and vegetables have been suggested to be responsible for their health benefits. Asparagus and one of its major phytochemical, Kaempferol, have been reported to have anti-cancer activities. However, the mechanisms of the anticancer activities are not completely understood. Seven varieties of asparagus were compared for their antioxidant content, antioxidant activities, and anticancer activities. The results showed that asparagus are rich in phenolic and flavonoids. They also show antioxidant activities in chemical assays and in vitro assays. Asparagus possesses potent anticancer abilities in inhibiting proliferation of HepG2 human liver cancer cells. Among the different varieties, Apollo has the highest phenolic content, flavonoid content, antioxidant activities, and anticancer activities. We further studied kaempferol’s effects in breast cancer cells growth and metastasis. The anti-proliferative activity and cytotoxicity of kaempferol against MCF-7 human breast cancer cells were measured by the methylene blue assay. All the key proteins regulating cell proliferation through signaling transduction pathways were determined by Western blot assay. Kaempferol exhibited potent anti-proliferative activity against MCF-7 human breast cancer cells in a dose-dependent manner.
    [Show full text]